Introduction {#S0001}
============

Due to the limited therapeutic options remaining to treat these infections, carbapenemase-producing Enterobacteriaceae (CPE) are increasingly important human pathogens associated with high mortality.[@CIT0001],[@CIT0002] Their spread is driven by two major forces: clonal dissemination of a few successful CPE lineages, and horizontal transfer of carbapenemase genes often located on epidemic plasmids spreading in different bacterial species, sources and countries.[@CIT0002]--[@CIT0005] Plasmids of the incompatibility group (Inc) X defined as X3 type (IncX3)[@CIT0006] have been reported worldwide in *Enterobacterales*, associated with*bla*~SHV-12~ extended-spectrum beta-lactamase (ESBL), *bla*~KPC-2,\ −3~, *bla*~NDM-1,\ −4,\ −5,\ −7~ and *bla*~OXA-181~ carbapenemase genes.[@CIT0007]--[@CIT0014] IncX3 plasmids were reported to disseminate a variety of *bla*~NDM~ genes in humans, in animals and in the environment particularly in South East Asia; including China, Hong Kong, South Korea, Myanmar, Vietnam and the Indian Subcontinent.[@CIT0012]--[@CIT0020]

The Middle-East is considered an endemic region for CPE, with the dominance of class D OXA-48-like, and class B NDM carbapenemases, with sporadic occurrence of class A KPC-2, and class B VIM-4 enzymes.[@CIT0001],[@CIT0002],[@CIT0007]--[@CIT0010] In the Arabian Peninsula autochthonous, clonal transmission has been implicated as the main driving force in the emergence of CPE,[@CIT0001] but plasmid-mediated dissemination of *bla*~VIM-4~ has also been documented in the region.[@CIT0021] Furthermore, sporadic isolates carrying *bla*~NDM-1~, *bla*~NDM-7~ and *bla*~KPC-2~ on IncX3 plasmids were identified in the United Arab Emirates (UAE).[@CIT0022]--[@CIT0024] However, the role of this type of plasmid in the dissemination of CPE, and its possible local evolution have not been systematically studied. Here, we present the comparisons of the complete sequences of IncX3 plasmids carrying various carbapenemase genes encountered in the UAE, and evaluate their relatedness to similar episomes identified worldwide.

Materials and methods {#S0002}
=====================

Bacterial strains {#S0002-S2001}
-----------------

Altogether 334 non-repeat carbapenem-resistant Enterobacterales (CRE) strains were tested. They were isolated between April 2009 and December 2014 in 12 hospitals of the UAE and submitted to the Department of Medical Microbiology and Immunology, UAE University, without any patient identifiers, to identify the carbapenemases produced. Strains were stored at −80°C in Tryptic Soy Broth (MAST, Merseyside, UK) containing 20% glycerol. This collection included 90 isolates described earlier in[@CIT0001],[@CIT0022]--[@CIT0024] and further 246 CRE isolated between May 2013 and December 2014 in six governmental hospitals of Abu Dhabi Emirate.

Detection of carbapenemase genes and screening for the IncX3 replicon {#S0002-S2002}
---------------------------------------------------------------------

The presence of the *bla*~NDM~, *bla*~OXA-48-like,~ *bla*~VIM~, *bla*~IMP~, *bla*~KPC~ carbapenemase genes, and that of *bla*~SHV~ were detected as described.[@CIT0025]--[@CIT0027] The specific alleles of beta-lactamase genes were determined by direct sequencing of the respective amplicons with the Big Dye Cycle Terminator V.3.1 (Applied Biosystems) using the 3130X Genetic Analyzer (Applied Biosystems). A replicase-specific PCR was used to screen strains for the presence of IncX3 plasmids.[@CIT0006]

Antibiotic susceptibility assays and phenotypic detection of carbapenemase production {#S0002-S2003}
-------------------------------------------------------------------------------------

The antibiotic susceptibility of carbapenemase-producing IncX3 plasmid carrying clinical isolates and their derivatives to cefotaxime, ceftazidime, aztreonam, ertapenem, meropenem, imipenem, ciprofloxacin, gentamicin, amikacin, trimethoprim/sulfamethoxazole, tetracycline and colistin was tested by broth microdilution, while fosfomycin and tigecycline susceptibilities were assessed by agar dilution.[@CIT0028] CLSI clinical breakpoints were used for interpretation for the majority of antibiotics.[@CIT0028] Results for colistin, tigecycline and fosfomycin were interpreted by the EUCAST criteria.[@CIT0029] Carbapenemase production was assessed phenotypically by the CIM test.[@CIT0030]

Molecular typing {#S0002-S2004}
----------------

Carbapenemase-producing IncX3 positive *K. pneumoniae, E. coli* and *E. cloacae* isolates were typed using pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST).[@CIT0031]--[@CIT0034]

Characterization of the carbapenemase gene-bearing IncX3 plasmids {#S0002-S2005}
-----------------------------------------------------------------

Plasmids were isolated by the alkaline lysis method, and detected as described in[@CIT0023] using *E. coli* 39R861 as plasmids\' molecular size standards. Southern blotting of the plasmid electrophoresis gel, and hybridization with IncX3 and the respective carbapenemase gene probes was used to prove the localization of carbapenemase genes on IncX3 plasmid.[@CIT0023]

The sequence of each IncX3 plasmids carried by different ST and/or PFGE profiles were further investigated. In case of multiple strains exhibiting the same ST and PFGE profile, plasmids were chosen from strains representing each unique plasmid profiles and/or coding for each distinct carbapenemases.

In mating out assays, a sodium-azide resistant derivative of rifampicin-resistant *E. coli* J53 (J53~RAZ~) was used as recipient. Transconjugants were selected on Tryptic Soy Agar containing 8 mg/L^−1^ ceftazidime and 100 mg/L^−1^ sodium-azide, or in case of OXA-181 producing clinical isolates on 0.5 mg/L^−1^ ertapenem and 100 mg/L^−1^ sodium-azide.[@CIT0035] When transconjugants were not obtained, the IncX3 plasmids were transformed into competent *E. coli* DH5α or *E. coli* GM2163.[@CIT0035] For complete plasmid sequencing, plasmid DNA was purified from single plasmid containing *E. coli* transconjugant or transformant using the Plasmid Maxi Prep kit (Qiagen, Hilden, Germany). The complete sequence of the plasmids was established by next-generation sequencing either by using the 454-Genome Sequencer FLX procedure (Roche Diagnostic, Monza, Milan, Italy) or, commercially, on the Illumina MiSeq platform (performed at the CCIB DNA Core Facility in Massachusetts General Hospital, Cambridge, MA, USA). The gaps between contigs assembled were closed by PCR and direct sequencing of the amplicons. The complete plasmid sequences were assembled with Clone Manager v9.0 (Sci-Ed Software, Cary, NC, US), annotated using Geneious R11.0.4 (Biomatters Ltd., Auckland, New Zealand) and Sequin (<http://www.ncbi.nlm.nih.gov/Sequin>), and submitted to GenBank (Accession numbers are shown in [Table 2](#T0004){ref-type="table"}).Table 1Distribution of IncX3 plasmid carrying isolates among strains expressing different carbapenem resistance mechanismsnAllNDMOXA-48-likeNDM and OXA-48-likeVIMKPCAll carbapenemase producerCarbapenemase non-producer33489126753229539IncX3 PCR positive32\
(9.6%)18\
(20%)6\
(4.8%)4\
(5.3%)02\
(100%)30\
(10.2%)2\
(5.1%) Table 2Characteristics of carbapenemase producing *Enterobacteriaceae* harboring IncX3 type plasmids with carbapenemase genesIsolatePlasmidRef.Name\*Date of isolationHospitalSpecimenSpeciesCarbapenemase producedMLSTC/Cm/nonCNameSize (bp)Resistance gene(s)GenBank Acc. NoABC13312/14/2012THSputum*E. coli*NDM-7ST4108nonCpABC133-NDM37070*bla*~NDM-7~KX214671[@CIT0024]**ABC239**8/15/2013RHUrine*E. coli*OXA-181ST410nonCpABC239-OXA-18151479*bla*~OXA-181~+ *qnrS1*MK412916This study**ABC264**6/9/2014THUnknown*E. coli*OXA-181ST410nonCpABC264-OXA-18151479*bla*~OXA-181~+ *qnrS1*MK412917This study**ABC356**8/8/2014MHUrine*E. coli*OXA-181ST410CmpABC356-OXA-18151479*bla*~OXA-181~+ *qnrS1*MK412918This study**ABC381**11/4/2014AAHRectal swab*E. coli*OXA-181ST167nonCpABC381-OXA-18151479*bla*~OXA-181~+ *qnrS1*MK412919This studyABC21812/25/2012RHWound*E. coli*NDM-7ST167CpABC218-NDM34403*bla*~NDM-7~KX214670[@CIT0024]**ABC233**7/21/2013RHUrine*E. coli*NDM-5ST167CmpABC233-NDM-546161*bla*~NDM-5~MK372390This study**ABC384**11/5/2014AAHUrine*E. coli*NDM-5ST1284CpABC384-NDM-546161*bla*~NDM-5~MK372389This study**ABC54**1/2/2011THUrine*E. coli*NDM-1ST2206CpABC54-NDM-153023*bla*~NDM-1~+ *bla*~SHV-12~MK372382This study**BC-13-836**9/24/2013THBlood*E. coli*NDM-1ST446CpBC836-NDM-152565*bla*~NDM-1~+ *bla*~SHV-11~MK372387This study**ABC280**7/15/2014THUrine*E. coli*NDM-5ST448CpABC280-NDM535502*bla*~NDM-5~MK372392This studyABC2868/15/2014THBlood*E. coli*NDM-5ST448NTNTNTNTNTThis study**ABC268**6/11/2014AAHUrine*E. coli*NDM-5ST2083CmpABC268-NDM-545232*bla*~NDM-5~MK372391This study**ABC40**10/27/2009THWound*E. cloacae*NDM-1ST417CmpABC40-NDM-154035*bla*~NDM-1~+ *bla*~SHV-12~MK372380This study**ABC302**2/26/2014MHUrine*E. cloacae*NDM-4ST200CABC302-NDM-449402*bla*~NDM-4~MK372388This study**BC-13-947**7/11/2013THBlood*K. pneumoniae*OXA-181ST2095nonCpBC947-OXA-18151479*bla*~OXA-181~+ *qnrS1*MK412920This study**ABC260**3/31/2014THRectal swab*K. pneumoniae*OXA-181ST3545nonCpABC260-OXA-18151480*bla*~OXA-181~+ *qnrS1*MK412915This study**ABC369**9/23/2014THAbdominal fluid*K. pneumoniae*NDM-5+ OXA-162ST307CmpABC369-NDM-545252*bla*~NDM-5~MK372393This study**ABC137**1/14/2013MHWound*K. pneumoniae*NDM-1+ OXA-48ST1318CmpABC137-NDM-153022*bla*~NDM-1~+ *bla*~SHV-12~MK372384This studyABC1414/20/2013MHUnknown*K. pneumoniae*NDM-1+ OXA-48ST1318NTNTNTNTNTThis studyABC1556/5/2013SKMCBlood*K. pneumoniae*NDM-1+ OXA-48ST1318NTNTNTNTNTThis studyABC22010/5/2012RHWound*K. pneumoniae*KPC-2ST14C^\#^pABC220-KPC-246900*bla*~KPC-2~MK412914This studyABC2243/17/2013RHSputum*K. pneumoniae*KPC-2ST14C^\#^NTNTNTNTThis study**ABC52**9/19/2010THSputum*K. pneumoniae*NDM-1ST11CpABC52-NDM-152565*bla*~NDM-1~+ *bla*~SHV-12~MK372381This studyABC539/19/2010THSputum*K. pneumoniae*NDM-1ST11NTNTNTNTNTThis studyBC6807/18/2012THBlood*K. pneumoniae*NDM-1ST11NTNTNTNTNTThis study**BC700**7/24/2012THBlood*K. pneumoniae*NDM-1ST11CpBC700-NDM-152565*bla*~NDM-1~+ *bla*~SHV-11~MK372386This studyBC-13-8179/17/2013THBlood*K. pneumoniae*NDM-1ST11NTNTNTNTNTThis study**ABC80**5/8/2011THUrine*Citrobacter freundii*NDM-1NTCmpABC80-NDM-153023*bla*~NDM-1~+ *bla*~SHV-12~MK372383This study**ABC140**3/25/2013MHPerianal swab*Morganella morganii*NDM-1NAnonCpABC140-NDM-152591*bla*~NDM-1~MK372385This study[^2][^3]

For comparison, all complete sequences of IncX3 plasmids carrying carbapenemase genes available in GenBank up to January 2019 were downloaded. If identical plasmid backbone sequences, carrying the same carbapenemase gene were identified in multiple isolates from the same country, only one was selected randomly for the phylogenetic analysis.

Plasmid backbones of the UAE IncX3 plasmid sequences and those retrieved from GenBank were aligned by ClustalW, and the evolutionary history was inferred by the Jukes-Cantor genetic distance model with 500x bootstrapping using Geneious R11.0.4 (Biomatters Ltd., Auckland, New Zealand).

Results {#S0003}
=======

Characteristics of strains carrying IncX3 plasmids {#S0003-S2001}
--------------------------------------------------

Of the 334 isolates screened, 295 were positive for at least one carbapenemase gene by PCR. The remaining 39 were negative by PCR for the five common carbapenemase genes tested, and they were carbapenemase non-producers by the CIM test. The distribution of the 32 IncX3 plasmid carrying isolates among strains with various carbapenem resistance genes is shown in [Table 1](#T0003){ref-type="table"}. The IncX3 positive CPE isolates were variably resistant to 3rd generation cephalosporins, aztreonam, aminoglycosides, ciprofloxacin, co-trimoxasole, tetracycline, tigecycline, colistin and fosfomycin (shown in [Table S1](#ST0001)). The characteristics of the 30 CPE isolates, in which at least one carbapenemase gene was located on an IncX3 plasmid, are shown in [Table 2](#T0004){ref-type="table"}. Altogether five species of *Enterobacterales* were identified. One *Citrobacter freundii*, one *Morganella morganii* and one *Enterobacter cloacae* carried *bla*~NDM-1~ on IncX3 plasmid, and a further *Enterobacter cloacae* harbored IncX3-borne *bla*~NDM-4.~

The 13 *E. coli* carried either *bla*~NDM-1~, *bla*~NDM-5~, *bla*~NDM-7~ or *bla*~OXA-181~ on IncX3 plasmids. They exhibited limited clonality; a triplet and two pairs of isolates formed PFGE clusters with ≥90% pattern similarity, respectively ([Figure S1A](#SF0001)). The 13 *E. coli* belonged to 8 different sequence types ([Table 2](#T0004){ref-type="table"}). The 13 *K. pneumoniae* were less heterogeneous: five *K. pneumoniae* ST11 carrying IncX3-borne *bla*~NDM-1~ exhibited ≥90% similar PFGE patterns, three NDM-1 and OXA-48 co-producing *K. pneumoniae* ST1318, with *bla*~NDM-1~ being located on IncX3 plasmid, also clustered by PFGE, and the two KPC-2 producer *K. pneumoniae* ST14 were indistinguishable by PFGE ([Figure S1B](#SF0001)). The further three K. pneumoniae were of different sequence types; two of them carried *bla*~OXA-181~, and one had *bla*~NDM-5~ on an IncX3 plasmid. This latter isolate, a *K. pneumoniae* ST307, co-produced NDM-5 and OXA-162, but *bla*~OXA-162~ was not located on the IncX3 plasmid ([Table 2](#T0004){ref-type="table"}).Figure S1(**A**) Comparison of pulsed-field gel electrophoresis patterns of *Escherichia coli* isolates. (**B**) Comparison of pulsed-field gel electrophoresis patterns of *Klebsiella pneumoniae* isolates.

Characteristics of IncX3 plasmids carrying carbapenemase genes {#S0003-S2002}
--------------------------------------------------------------

Altogether 21 IncX3 plasmids were selected for further analysis. Single plasmid-bearing derivatives obtained by conjugation or by transformation ([Table 2](#T0004){ref-type="table"}) showed varying degrees of non-susceptibility to carbapenems and to 3rd generation cephalosporins and were susceptible to non-beta lactam antibiotics ([Table S1](#ST0001)).

Complete DNA sequences of the 21 plasmids were obtained and compared to two IncX3 plasmids carrying *bla*~NDM-7~ (pABC133-NDM and pABC218-NDM), previously described from the UAE[@CIT0024] ([Table 2](#T0004){ref-type="table"} and [Figure 1](#F0001){ref-type="fig"}).Figure 1Comparison of IncX3 plasmids from the United Arab Emirates carrying various carbapenemases.**Notes:** Grey shades represent regions with ≥99% similarity.

In pABC220-KPC-2, the *bla*~KPC-2~ gene was located on a Tn*4401b* transposon, and no further resistance gene was carried by this plasmid.

The six *bla*~OXA-181~ carrying plasmids were \>99% similar to each other, and all of them harbored the *bla*~OXA-181~ and a *qnrS1* quinolone resistance gene in a composite transposon bracketed by IS*26*.

The genetic load region of the eight *bla*~NDM-1~ carrying plasmids was flanked by IS*26* and Tn*3*. The immediate genetic surrounding of the *bla*~NDM-1~ between an IS*CR27* and a truncated IS*Aba125* was identical in all eight plasmids. The IS*26* bracketed composite transposon upstream of IS*CR27* either carried *bla*~SHV-11~ (n=2), or *bla*~SHV-12~ (n=5), or contained a truncated Tn*3* transposase (pABC140-NDM-1). The genetic surroundings of *bla*~NDM-4,~ *bla*~NDM-5~ and *bla*~NDM-7~ between IS*26* and IS*5* were identical.

Although the genetic load regions were different in plasmids having various classes of carbapenemases, the plasmid backbones were highly similar with the notable absence of *hns*, and variable presence of complete or truncated *topB* and *ATPase* genes in pABC280-NDM-5, pABC218-NDM and pABC133-NDM ([Figure 1](#F0001){ref-type="fig"}).

Phylogenesis of the carbapenemase gene-bearing IncX3 plasmids {#S0003-S2003}
-------------------------------------------------------------

As pABC218-NDM, despite a large deletion in the conserved region, demonstrated to be self-conjugative and sufficiently stable, a 24905 bp long region coding for its replication, partitioning and transfer (from position 1286 to 26190 in GenBank Acc. No. KX214670) was used in the phylogenetic analysis. This backbone region was extracted from all complete IncX3 plasmid sequences from the UAE, and from the complete sequence of 35 IncX3 plasmids from different geographical regions downloaded from GenBank (listed in [Table S2](#ST0002)).

The Neighbor-Joining tree of the 58 IncX3 plasmid backbone sequences ([Figure 2](#F0002){ref-type="fig"}) showed three distinct clades. The first contained *bla*~NDM-1,~ *bla*~NDM-4~ and *bla*~NDM-7~ carrying plasmids from the UAE and plasmids carrying similar carbapenemase genes of other geographical regions, and a *bla*~SHV-12~ carrying plasmid from The Netherlands. The second one included *bla*~NDM-5~ carrying plasmids, and the third clade clustered *bla*~OXA-181~ carrying IncX3 plasmids originating from various parts of the world with a single outlier of *bla*~OXA-181~ carrying IncX3 plasmid (MG228426) from Italy only. Conversely, plasmids harboring *bla*~KPC~ were distinct from each other.Figure 2Phylogenetic tree of backbone sequences of IncX3 plasmids from various geographical area.**Notes:** The sequences were aligned using ClustalW, and the Neighbor-Joining tree was constructed using the Jukes-Cantor genetic distance model with 500 bootstrap replicates. All positions containing gaps and missing data were eliminated. There was a total of 24,868 positions in the final dataset. Plasmid names printed in bold represent IncX3 plasmids from the UAE, for plasmids retrieved from GenBank the accession number, the beta-lactamase gene carried, and the country of isolation is shown.**Abbreviations:** CA, Canada; CH, Switzerland; CN, China; CZ, Czech Republic; DN, Denmark; FR, France; GR, Germany; HK, Hong Kong; IN, India; IT, Italy; KR, South Korea; KW, Kuwait; LB, Lebanon; MY, Myanmar; NL, the Netherlands; OM, Oman; US, United States of America.

Discussion {#S0004}
==========

Our data showed that in CRE isolated in 12 hospitals of the UAE, the overall prevalence of IncX3 plasmids was 9.6%, and in NDM-producer as high as 20%. Importantly, in the 30 CPE, the carbapenemase gene (or one of them in the double carbapenemase producers) was located on an IncX3 type plasmid. This is a prevalence substantially higher than the one reported in human fluoroquinolone or cefotaxime resistant *E. coli* isolates,[@CIT0007] but considerably lower compared to a report on CRE from Hong Kong (30.3%).[@CIT0012]

The CRE isolates carrying IncX3 with a carbapenemase gene were quite diverse. They belonged to five different species of *Enterobacterales* (*K. pneumoniae, E. coli, E. cloacae, C. freundii* and *M. morgannii*). Similar, or even higher diversity of hosts of carbapenemase bearing IncX3 plasmids has been noted in South-East Asian countries.[@CIT0012],[@CIT0016] The majority of CRE isolates carrying carbapenemase-encoding IncX3 plasmids were unrelated. However, PFGE clustering of five *K. pneumoniae* ST11 harboring *bla*~NDM-1~ on IncX3 plasmids, all isolated in the same hospital, suggested clonal dissemination. Interestingly, the two plasmids sequenced from these five isolates carried different *bla*~SHV~ alleles: *bla*~SHV-12~ and *bla*~SHV-11~ differing in three nucleotides, otherwise being 100% identical to each other. The combination of carbapenemase carrying IncX3 plasmid and the *K. pneumoniae* ST11 clone, both considered to have epidemic potential,[@CIT0005] is especially worrisome.

Interestingly, two *K. pneumoniae* ST14, which were described earlier in,[@CIT0022] carried *bla*~KPC-2~, although this clone was found to be the most common NDM- and OXA-48-like producer *K. pneumoniae* clone in Dubai in a later period, when no KPC-producing isolates were encountered.[@CIT0036]

A member of another high-risk *K. pneumoniae* clone, ST307, was also encountered possessing *bla*~OXA-162~ and an IncX3 plasmid-borne *bla*~NDM-5~. To the best of our knowledge, *bla*~OXA-162~ has not previously been associated with this clone. It is noteworthy that the same ST had been reported earlier from the UAE to carry *bla*~NDM-1~ on an IncHI1B plasmid and *bla*~OXA-162~ on IncL/M plasmid.[@CIT0035] While that isolate did not harbor an IncX3 plasmid, it was recovered in the same hospital as the current one with the IncX3 *bla*~NDM-5~ plasmid, and was also co-harboring a *bla*~OXA-162~. Therefore, the possibility of local acquisition of *bla*~NDM-5~ carrying IncX3 plasmid cannot be excluded.

A cluster of three OXA-181 producing *E. coli* ST410 harboring the carbapenemase on IncX3 plasmids was also encountered. Recently, it was established that this sequence type of *E. coli* is also an emerging high-risk clone.[@CIT0037] The three *E. coli* ST167 isolates carried three different carbapenemases: *bla*~NDM-5,~ *bla*~NDM-7~ and *bla*~OXA-181~, all located on IncX3 plasmids ([Table 2](#T0004){ref-type="table"}). This clone is considered to be an epidemic NDM-5-producing *E. coli* clone in China[@CIT0038] and was shown to carry IncX3 plasmid-borne *bla*~NDM-5~ in the Czech Republic, too.[@CIT0039] It was also reported to harbor *bla*~NDM-7~ on IncX3 plasmid from France[@CIT0040] and India.[@CIT0041] However, *E. coli* ST167 with *bla*~OXA-181~ carrying IncX3 plasmid has not been encountered yet, although a single locus variant of ST167 was reported to carry this carbapenemase gene from São Tomé and Príncipe.[@CIT0042]

It has been suggested that the wide dissemination of IncX3 plasmids is due to its highly efficient conjugal transfer, contributing to its spread within clinical settings, as well as in the environment.[@CIT0012],[@CIT0016] Based on our studies we cannot comment on these observations, since several of our plasmids co-transferred with other episomes, and some were non-conjugative, despite genes for conjugal transfer were apparently present and intact in all but one plasmid of our collection (pABC133-NDM described in[@CIT0024]). Similarly, we cannot comment on the role of the environmental dissemination suggested earlier,[@CIT0012],[@CIT0024],[@CIT0043] as the current study included human isolates only.

Since many, but not all, carbapenemase carrying IncX3 plasmids resided in international high-risk clones of *Enterobacteriaceae*, we compared the conserved regions of plasmids from the UAE to the ones reported earlier from various countries ([Table S2](#ST0002)) to evaluate whether these plasmids occur in the UAE as a result of local evolution, or rather as a consequence of international transfer. The analysis identified clades exhibiting good correlation with the carbapenemase genes carried ([Figure 2](#F0002){ref-type="fig"}), ie close phylogenetic relationship of IncX3 plasmids harboring *bla*~NDM-1,~ *bla*~NDM-4~ and *bla*~NDM-7~ from the UAE and from different countries of the Middle-East, Asia, Europe and North-America was observed. On the other hand, *bla*~NDM-5~ carrying plasmids from the UAE, Czech Republic, China, Hong Kong, India and South Korea formed a distinct clade. Previously, based on the high degree of synteny among the complete NDM-IncX3 plasmid sequences, the evolution of *bla*~NDM~ alleles within the IncX3 plasmid was suggested.[@CIT0012] Our findings partially support this hypothesis with the notion that certain *bla*~NDM~ alleles, notably that of NDM-5, are located on plasmids with a more distantly related backbone, suggestive of multiple uptakes of *bla*~NDM~ genes by these plasmids.

*bla*~OXA-181~ carrying IncX3 plasmids encountered in the UAE, as well as in Lebanon, Germany, Denmark, Czech Republic, Switzerland, China, South Korea and Myanmar formed another distinct clade with a single outlier (MG228426) from Italy, only. The KPC-IncX3 plasmids were phylogenetically heterogeneous: while two *bla*~KPC-2~ harboring plasmids from Hong Kong and from France mapped relatively close (JX104759 and JX461340), the backbone of the plasmid coding for the same allele from of the UAE (pABC220-KPC-2) and that of an Italian plasmid carrying *bla*~KPC-3~ (KT362706) were distant.

Conclusion {#S0005}
==========

Phylogenetic analysis, clustering backbones of IncX3 plasmids of diverse geographical origin based on the carbapenemase gene carried, suggests that these plasmids disseminate across the continents. Consequently, the emergence of different carbapenemase carrying IncX3 plasmids in the UAE is likely not the result of local evolution, but due to the international transfer of such plasmids. Moreover, finding of high-risk *K. pneumoniae* and *E. coli* clones in the UAE, harboring these plasmids, warrants further studies to better understand the role of the epidemic plasmids and clones in the emergence and spread of CPE in the country highly exposed to international travel and trade.
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Table S1Antibiotic susceptibility of clinical isolates carrying carbapenemases on IncX3 plasmids and their single IncX3 plasmid containing derivativesStrainCarbapenemase producedWild type/transconjugant/transformantErtapenemImimpenemMeropenemCeftazidimeCefotaximeAztreonamCiprofloxacinGentamicinAmikacinCo-trimoxazoleTetracyclineColistinTigecyclineFosfomycinABC220KPC-2WT25664128\>128\>128\>1286425616\>2564320.5256GM3163(pABC220-KPC-2)KPC-2TF442164\>128≤0.12511≤0.5≤0.5≤0.5≤0.12516ABC224KPC-2WT25664128\>128\>128\>1283225632\>2564320.5128ABC140NDM-1WT2328128324824≤0.516\>2564\>512DH5α(pABC140-NDM-1)NDM-1TF0.52≤0.25\>1286432≤0.125≤0.52≤0.6≤0.5≤0.5≤0.125≤0.25ABC40NDM-1WT321616\>128\>128\>128\>641284≤0.7256218J53RAZ(pABC40-NDM-1)NDM-1TC0.2544\>1286432≤0.125≤0.5≤0.5≤0.8≤0.5≤0.5≤0.1250.5ABC52NDM-1WT643264\>128\>128\>128\>64\>256\>256\>2564≤0.514J53RAZ(pABC52-NDM-1)NDM-1TC148\>1286464≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.1251ABC53NDM-1WT646464\>128\>128\>128\>64\>256\>256\>2564≤0.5216ABC54NDM-1WT81616\>128128\>1280.2514\>256128≤0.50.250.5DH5α(pABC54-NDM-1)NDM-1TF0.2544\>1286432≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.1250.5ABC80NDM-1WT884\>128128\>1284321128≤0.5≤0.50.250.5J53RAZ(pABC80-NDM-1)NDM-1TC0.584\>1286432≤0.1251≤0.5≤0.5≤0.5≤0.5≤0.1250.5BC680NDM-1WT163264\>128\>128\>128\>64416\>2562≤0.524BC700NDM-1WT166432\>128\>128\>128\>64216\>2562≤0.524J53RAZ(pBC700-NDM-1)NDM-1TC244\>12864≤0.25≤0.1251≤0.5≤0.5≤0.5≤0.5≤0.1250.5BC-13-817NDM-1WT163232\>128\>128\>128\>64416\>2562≤0.524BC-13-836NDM-1WT41616\>128\>128≤0.25≤0.12524≤0.5128≤0.5≤0.1250.5DH5α(pBC836-NDM-1)NDM-1TF0.252≤0.25\>12864≤0.25≤0.125≤0.51≤0.5≤0.5≤0.5≤0.125≤0.25ABC141NDM-1+ OXA-48WT166432\>128\>128\>128\>641288\>256\>2564168ABC155NDM-1+ OXA-48WT\>256\>128\>128\>128\>128\>12841284\>256\>256≤0.52128ABC137NDM-1+ OXA-48WT166432\>128\>128\>12841284\>256\>256≤0.528J53RAZ(pABC137-NDM-1)NDM-1TC0.2544\>1286432≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.1250.5ABC302NDM-4WT12864128\>128\>128\>12864\>256\>256\>2568≤0.5216DH5α(pABC302-NDM-4)NDM-4TF0.252≤0.25\>12864≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC233NDM-5WT321632\>128\>128\>128\>64\>256\>2561281≤0.5≤0.1250.5DH5α(pABC233-NDM-5)NDM-5TF0.52≤0.25\>12864≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC268NDM-5WT321632\>128\>12832\>646442561≤0.50.251DH5α(pABC268-NDM-5)NDM-5TF0.252≤0.25\>12864≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC280NDM-5WT321616\>128\>128\>128\>64648\>2561≤0.50.251J53RAZ(pABC280-NDM-5)NDM-5TC0.548\>128128≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.1251ABC286NDM-5WT64832\>128\>128\>128\>643242561≤0.50.251ABC384NDM-5WT6412832\>128\>128\>128\>64648256\>256≤0.5≤0.1250.5J53RAZ(pABC384-NDM-5)NDM-5TC0.2544\>12864≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.1251ABC369NDM-5+ OXA-162WT488\>128\>128\>128\>64256\>256\>2564≤0.524DH5α(pABC369-NDM-5)NDM-5TF0.252≤0.25\>12864≤0.25≤0.125≤0.51≤0.5≤0.5≤0.5≤0.125≤0.25ABC133ETPNDM-7WT128128128\>128\>12864\>64648≤0.5\>256≤0.50.250.5DH5α(pABC133-NDM)NDM-7TF142\>12864≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC218NDM-7WT641632\>128\>128\>128\>6425682561≤0.5≤0.1250.5J53RAZ(pABC218-NDM)NDM-7TF288\>128128≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.1251ABC239OXA-181WT20.5≤0.25\>128\>128\>128\>641288\>256\>256≤0.5≤0.1250.5DH5α(pABC239-OXA-181)OXA-181TF0.5≤0.25≤0.25≤0.25≤0.25≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC260OXA-181WT1286432220.51611\>2564162\>512DH5α(pABC260-OXA-181)OXA-181TF≤0.125≤0.25≤0.25≤0.25≤0.25≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC264OXA-181WT21≤0.25\>128\>128\>128\>6444256\>256≤0.50.251DH5α(pABC264-OXA-181)OXA-181TF≤0.125≤0.25≤0.25≤0.25≤0.25≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC356OXA-181WT210.5\>128\>128\>128\>641288\>256\>256≤0.50.250.5DH5α(pABC356-OXA-181)OXA-181TF0.25≤0.25≤0.25≤0.25≤0.25≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25ABC381OXA-181WT1688\>12812886422256256≤0.50.25≤0.25DH5α(pABC381-OXA-181)OXA-181TF≤0.125≤0.25≤0.25≤0.25≤0.25≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25BC-13-936OXA-181WT0.2520.5≤0.25≤0.25≤0.25122\>2561≤0.50.2516BC-13-947OXA-181WT≤0.12520.516264122\>256180.2516DH5α(pBC947-OXA-181)OXA-181TF≤0.125≤0.25≤0.25≤0.25≤0.25≤0.25≤0.125≤0.5≤0.5≤0.5≤0.5≤0.5≤0.125≤0.25BC-13-970OXA-181WT0.2520.50.5≤0.25≤0.25122\>2561≤0.50.2516DH5αNoneR≤0.125≤0.25≤0.25≤0.25≤0.25≤0.25≤0.12511≤0.5≤0.5≤0.5≤0.125≤0.25GM2163NoneR≤0.125≤0.25≤0.25≤0.25≤0.25≤0.25≤0.12524≤0.5≤0.5≤0.5≤0.12516J53RazNoneR≤0.125≤0.25≤0.25≤0.25≤0.25≤0.25≤0.1251≤0.5≤0.5≤0.5≤0.5≤0.1250.5 Table S2IncX3 plasmids (retrieved from GenBank in January 2019) from different geographical regions with unique backbone sequences and beta-lactamase genes carriedResistance genesCountryNameGenBank Accession No*bla*~KPC-2~Hong KongpKPC-NY79JX104759*bla*~NDM-17~ChinapAD-19RKX833071*bla*~NDM-4~MyanmarpM216_X3AP018146*bla*~NDM-4~AustraliapJEG027KM400601*bla*~NDM-4~Czech RepublicpEncl-922czMG252892*bla*~NDM-5~Czech RepublicpEsco-5256czMG252891*bla*~NDM-5~IndiapNDM-MGR194KF220657*bla*~NDM-5~Hong KongpNDM-HK2998MH234508*bla*~NDM-5~Hong KongpNDM-HK2967MH234509*bla*~NDM-5~South KoreapCREC-591_4CP024825*bla*~NDM-7~South KoreapCREC-532_3CP024833*bla*~NDM-7~OmanpOM26-NDMKP776609*bla*~NDM-7~KuwaitpKW53T-NDMKX214669*bla*~NDM-7~CanadapKpN01-NDM-7CP012990*bla*~NDM-7~MyanmarpM110-X3AP018141*bla*~NDM-7~ChinapEC50-NDM-7KX470735*bla*~OXA-181~ItalypKP_BO_OXA-181MG228426*bla*~OXA-181~, *qnr*S1ChinapOXA-181KP400525*bla*~OXA-181~, *qnr*S1SwitzerlandpKS22KT005457*bla*~OXA-181~, *qnr*S1GermanypOXA-181-IHIT35346KX894452*bla*~OXA-181~, *qnr*S1South KoreapD6-OXA_1\_1MG702491*bla*~OXA-181~, *qnr*S1MyanmarpM206-OXA181AP018831*bla*~OXA-181~, *qnr*S1Czech RepublicpOXA181_29144KX523903*bla*~OXA-181~, *qnr*S1LebanonpSTIB_IncX3_OXA_181MG570092*bla*~OXA-181~, *qnr*S1DenmarkpAMA1167-OXA-181CP024806*bla*~SHV-11~ItalypIncX-SHVJN247852*bla*~SHV-11~, *bla*~KPC-3~Italyp45-IncX3KT362706*bla*~SHV-12~NetherlandspEC-393KX618697*bla*~SHV-12~NetherlandspEC-125KX618703*bla*~SHV-12~, *aac(6ʹ)-Ib*USApKPN-819CP008799*bla*~SHV-12~, *bla*~KPC-2~FrancepKpS90JX461340*bla*~NDM-1~+ *bla*~SHV-12~ChinapNDM-HN380JX104760*bla*~NDM-1~+ *bla*~SHV-12~Hong KongpNDM-HK3694MH234505*bla*~SHV-12~, *bla*~TEM-1~, *qnr*S1NetherlandspEC-NRS18KX618696NoneUSApUCLAOXA232-2CP012563

[^1]: These authors contributed equally to this work

[^2]: **Notes:** \*Strain names with bold indicate those from which the IncX3 plasmid was fully sequenced in this study.

[^3]: **Abbreviations:** MLST, Multi-Locus Sequence Typing; ST, sequence type; NA, not applicable; NT, not tested; C, conjugative; Cm, conjugative with transconjugants having multiple plasmids; C^\#^, conjugative, but cannot stably maintained in *E. coli* J53~RAZ~; nonC, not self-transmissible.
